Hodgkin's Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
Discover the latest drugs and treatment options in the Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Hodgkin's Lymphoma Pipeline Outlook
Key Takeaways from the Hodgkin's Lymphoma Pipeline Report
In May 2025, Celgene announced a phase II study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.
In May 2025, Hoffmann-La Roche conducted a Phase I/II study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab.
In May 2025, Bristol-Myers Squibb organized a study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
DelveInsight's Hodgkin's Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin's Lymphoma treatment.
The leading Hodgkin's Lymphoma Companies such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
Promising Hodgkin's Lymphoma Pipeline Therapies such as HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.
Stay ahead with the most recent pipeline outlook for Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hodgkin's Lymphoma Treatment Drugs
Hodgkin's Lymphoma Emerging Drugs Profile
AFM 13: Affimed Therapeutics
AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is most advanced ICE® clinical program and was evaluated as monotherapy in a Phase IIB trial in patients with relapsed/refractory peripheral T cell lymphoma (REDIRECT). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. Currently it is in Phase II stage of clinical trial evaluation to treat Hodgkin's Lymphoma.
AUR105 : Aurigene Oncology
AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications like solid tumor, non-Hodgkin lymphoma, leukemia or Hodgkin lymphoma. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma.
The Hodgkin's Lymphoma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin's Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma Treatment.
Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin's Lymphoma market
Explore groundbreaking therapies and clinical trials in the Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Hodgkin's Lymphoma Drugs
Hodgkin's Lymphoma Companies
Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
Hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical
Hodgkin's Lymphoma Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Unveil the future of Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hodgkin's Lymphoma Market Drivers and Barriers
Scope of the Hodgkin's Lymphoma Pipeline Report
Coverage- Global
Hodgkin's Lymphoma Companies- Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
Hodgkin's Lymphoma Pipeline Therapies- HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.
Hodgkin's Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hodgkin's Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hodgkin's Lymphoma Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Hodgkin's Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hodgkin's Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid-Stage Products (Phase II)
AFM13: Affimed Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AUR105 : Aurigene Oncology
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Hodgkin's Lymphoma Key Companies
Hodgkin's Lymphoma Key Products
Hodgkin's Lymphoma- Unmet Needs
Hodgkin's Lymphoma- Market Drivers and Barriers
Hodgkin's Lymphoma- Future Perspectives and Conclusion
Hodgkin's Lymphoma Analyst Views
Hodgkin's Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
34 minutes ago
- Globe and Mail
Echelon Risk + Cyber Debuts in the Top 10% of the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
Echelon Risk + Cyber, a leader in cybersecurity and risk management services, has earned a spot in the top 10% of the prestigious 2025 Inc. 5000 list of America's fastest-growing private companies. In its very first year on the list, Echelon ranked No. 433 overall and seventh among all companies in Pennsylvania, making it top of the list for companies headquartered in Pittsburgh. The Inc. 5000 list is the most trusted annual ranking of entrepreneurial success in the U.S., spotlighting independent businesses that are driving growth, innovation, and job creation. 'This recognition is a direct reflection of our values in action,' said Dan Desko, CEO and Co-Founder of Echelon Risk + Cyber. 'Breaking into the top 10% on our first attempt shows what's possible when you combine a team of true professionals with a shared commitment to doing the right thing, the right way, every time. We succeed because our clients trust us with what matters most, and our team shows up every day ready to earn that trust. Being the leading Pittsburgh-based company on the list makes it even sweeter, because it shows that world-class innovation and execution can thrive right here in our hometown.' 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' says Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' For the full list, company profiles, and a searchable database by industry and location, visit: About Echelon Risk + Cyber Echelon Risk + Cyber is a cybersecurity professional services firm built on the belief that privacy and security are basic human rights. Echelon's comprehensive suite of services are customized and right-sized for each client, helping to solve even the most complex cybersecurity issues. Services include vCISO-Led Security Team as a Service, Offensive Security Consulting & Adversarial Simulation, Defensive Security Consulting & Hardening, and Cyber Risk Advisory & Compliance. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit Media Contact Company Name: Echelon Risk + Cyber Contact Person: Marissa Salzone Email: Send Email Country: United States Website:
Globe and Mail
40 minutes ago
- Globe and Mail
Plug Power Inc. Reports Strong Q2 2025 Growth
Plug Power Inc ( (PLUG)) has released its Q2 earnings. Here is a breakdown of the information Plug Power Inc presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Plug Power Inc., a pioneer in hydrogen solutions, is at the forefront of the hydrogen economy, offering a comprehensive ecosystem for production, storage, delivery, and power generation across various industries. In its latest earnings report for the second quarter of 2025, Plug Power highlighted significant revenue growth and strategic advancements, underscoring its expanding role in the global hydrogen market. The company reported a 21% year-over-year increase in revenue, reaching $174 million, driven by strong demand for its GenDrive fuel cells, GenFuel infrastructure, and GenEco electrolyzer platforms. Notably, the revenue from electrolyzers tripled, reflecting Plug Power's successful global scaling efforts. The company also made substantial improvements in its gross margin, which rose to -31% from -92% the previous year, thanks to cost reductions and improved pricing strategies. Strategically, Plug Power is advancing its Project Quantum Leap, which has been instrumental in optimizing costs and enhancing operational efficiency. The company has consolidated facilities, optimized its workforce, and renegotiated supply contracts to further improve its financial performance. Additionally, Plug Power's GenEco electrolyzer programs are gaining traction globally, with significant deployments across Europe, Australia, and North America, reinforcing its leadership in industrial-scale hydrogen solutions. Looking ahead, Plug Power is poised for continued growth, with expectations to achieve gross margin breakeven by the fourth quarter of 2025. The company is leveraging tax credits and strategic partnerships to enhance its market position and capitalize on the growing demand for hydrogen solutions. As Plug Power continues to expand its hydrogen production network and explore new revenue opportunities, it remains committed to advancing energy independence and decarbonization on a global scale.
Globe and Mail
40 minutes ago
- Globe and Mail
BigBear.ai Reports Q2 2025 Results and Growth Plans
Bigbear. Ai Holdings, Inc. ( (BBAI)) has released its Q2 earnings. Here is a breakdown of the information Holdings, Inc. presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Holdings, Inc. is a prominent provider of AI-powered decision intelligence solutions, primarily serving sectors such as national security, defense, and enterprise. The company is known for its predictive analytics capabilities in complex, mission-based environments. In its latest earnings report, announced a sequential improvement in its balance sheet, achieving a record cash balance of $390.8 million as of June 30, 2025. The company also updated its financial outlook, projecting full-year revenue between $125 million and $140 million. The second quarter of 2025 saw revenue decrease by 18% to $32.5 million compared to the same period in 2024, primarily due to reduced volume in certain Army programs. The company reported a net loss of $228.6 million, significantly impacted by non-cash changes in derivative liabilities and a goodwill impairment charge. Despite these challenges, the company has a backlog of $380 million, reflecting potential future revenue. Strategically, is positioning itself for growth through significant investments, supported by its robust cash position. The company is eyeing opportunities from the 'One Big Beautiful Bill,' which promises substantial funding for national security and defense technology. Additionally, is expanding internationally, having signed a transformative partnership with companies in the UAE. Looking ahead, remains optimistic about its growth prospects, despite disruptions in federal contracts. The company plans to leverage its strong cash reserves to make strategic investments, both organically and inorganically, to drive future growth.
